News |

AskGene Pharma Announces First Development Milestone in License Agreement with AffaMed for the Development of ASKG712 in Retinal Disease

Camarillo, California, June 20, 2022 – AskGene Pharma Inc., an innovative clinical-stage biotech company, announces that its partner AffaMed has dosed the first patient in Read More
News |

ASKB589 Achieved Partial Response in Phase I/II Clinical Trial

News, 2022-04-29 AskGene is pleased to announce that its lead program ASKB589 has recently achieved single agent efficacy in its on-going Phase I/II clinical trial. Read More
News |

AM712 (ASKG712) IND Filing in USA

AffaMed Therapeutics (“AffaMed”), in collaboration with Askgene, announces that the United States Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application Read More
News |

ASKG712 IND Filing in China

(Camarillo, California and Nanjing, Jiangsu Province, China) Askgene announces the acceptance of IND to initiate a clinical trial of ASKG712 to treat nAMD (neovascular age Read More
News |

GenScript Partnership

On September 26, 2021, GenScript ProBio and AskGene signed a license agreement for GenScript ProBio's single-domain antibody (sdAb) targeting an immune checkpoint target. GenScript ProBio Read More
News |

AskGene Pharma Signs a Patent Licensing Agreement

As a subsidiary of Aosaikang Pharm (SZ002755), Askgene Pharma (AskGene) signed a patent licensing agreement (Cross-License Agreement) with Xilio Therapeutics (Xilio), the news was announced Read More